Diversity & Inclusion
The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.
Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Friday, 8 March is International Women’s Day, and to celebrate, Citeline spoke to female leaders from across the medtech sector about their experiences as women, women-specific issues that technology can address, and how they can empower others to reach similar – or even greater – levels of success. Take a look at some interview snapshots below:
In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.
Equality, Diversity and Inclusion (ED&I) carries huge potential for business and society. However, various events around the globe, including the Black Lives Matter movement, highlighted that there are unaddressed challenges which need to be tackled. PTC Therapeutics, a global biopharmaceutical company with presence in in Europe, Middle East and Africa (EMEA) has initiated a new ED&I program to further strengthen its values and encourage positive progress globally.
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
This year marks the 30th anniversary of the NIH revitalization act that required women and minorities to be included in clinical research in the US. Putting that into perspective, we have only really been collecting data at scale on women and minorities since the movie Jurassic Park was launched. If we want more people to participate in clinical trials, it is time to get real about reducing the burden of research on volunteers.
LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.
With a growing focus on clinical trial diversity, companies are looking for ways to recruit from historically marginalized communities. Machine learning may help meet these diversity goals.
Urmi Prasad Richardson brings a wealth of science and business experience to diagnostics and life sciences multinational Thermo Fisher Scientific, where for the past two years she has been president of the group’s vast and varied EMEA business. The Indian-born, Germany-based executive has surmounted a range of challenges along the way and offers her story as inspiration for others.
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.
The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.
For all its good intentions and lauded action toward gender equality, the biotech industry in Scandinavia and the Nordics has a female CEO rate hovering around 23%. While the number of women entering academia, innovative companies and laboratories is healthy, gender equality in the C-suite leaves a lot to be desired.
The next generation of consumer health care products and services will have a digital element, which is why Haleon, a listed company that demerged from GSK in 2022, has set up a digital incubator to attract innovations and promote collaborations. Senior Haleon executives explain the rationale.
Attracting and retaining talent is harder than ever for medtech companies. Changing lifestyles, the expectation that loyalty will be less rewarding than job hopping, and various other economic and social factors have all helped contribute to chronic staffing shortages throughout medtech.
In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.